Form 4: Neurocrine Biosciences Executive Julie Cooke Executes Stock Option and Sells Shares Under 10b5-1 Plan

Julie Cooke, Chief Human Resources Officer of Neurocrine Biosciences, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 16, 2024, Julie Cooke, Chief Human Resources Officer of Neurocrine Biosciences, exercised options to acquire 900 shares of common stock at a price of $61.82 per share.
• Simultaneously, Cooke sold 900 shares of common stock at a weighted average price of $150.04 per share, with individual sales ranging from $150.00 to $150.18.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on March 14, 2024.
• Following these transactions, Cooke directly owns 18,202 shares and indirectly owns 16,538 shares through the Cooke Family Trust of 2004.
• Cooke also holds options for 12,632 shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, reflecting routine transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Rule 10b5-1 plans allow insiders to sell shares at predetermined times to avoid accusations of trading on inside information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.

Key Dates